Zevra Therapeutics, Inc. NASDAQ:ZVRA

Zevra Therapeutics stock price today

$9.18
+0.78
+9.42%
Financial Health
0
1
2
3
4
5
6
7
8
9

Zevra Therapeutics stock price monthly change

+43.42%
month

Zevra Therapeutics stock price quarterly change

+43.42%
quarter

Zevra Therapeutics stock price yearly change

+53.10%
year

Zevra Therapeutics key metrics

Market Cap
449.42M
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-1.35
Revenue
28.00M
EBITDA
-51.52M
Income
-50.90M
Revenue Q/Q
18.96%
Revenue Y/Y
198.83%
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
-183.98%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Zevra Therapeutics stock price history

Zevra Therapeutics stock forecast

Zevra Therapeutics financial statements

Zevra Therapeutics, Inc. (NASDAQ:ZVRA): Profit margin
Jun 2023 8.47M -5.08M -60.02%
Sep 2023 2.89M -14.04M -485.15%
Dec 2023 13.21M -15.15M -114.65%
Mar 2024 3.42M -16.62M -485.31%
Zevra Therapeutics, Inc. (NASDAQ:ZVRA): Analyst Estimates
Sep 2025 21.14M -6.44M -30.47%
Oct 2025 21.29M -5.43M -25.51%
Dec 2025 22.04M -2.17M -9.88%
Dec 2025 24.73M -2.92M -11.82%
  • Analysts Price target

  • Financials & Ratios estimates

Zevra Therapeutics, Inc. (NASDAQ:ZVRA): Debt to assets
Jun 2023 105518000 37.01M 35.08%
Sep 2023 138982000 71.51M 51.45%
Dec 2023 172327000 110.46M 64.1%
Mar 2024 151283000 102.46M 67.73%
Zevra Therapeutics, Inc. (NASDAQ:ZVRA): Cash Flow
Jun 2023 -8.70M 34.03M 951K
Sep 2023 -4.62M -44.45M 26.25M
Dec 2023 -16.15M 10.58M 5.00M
Mar 2024 -16.16M 14.79M 1.21M

Zevra Therapeutics alternative data

Zevra Therapeutics, Inc. (NASDAQ:ZVRA): Employee count
Aug 2023 32
Sep 2023 32
Oct 2023 32
Nov 2023 32
Dec 2023 32
Jan 2024 32
Feb 2024 32
Mar 2024 32
Apr 2024 32
May 2024 65
Jun 2024 65
Jul 2024 65

Zevra Therapeutics other data

Tuesday, 17 December 2024
globenewswire.com
Friday, 6 December 2024
globenewswire.com
Tuesday, 26 November 2024
globenewswire.com
Thursday, 21 November 2024
globenewswire.com
Wednesday, 13 November 2024
seekingalpha.com
Tuesday, 12 November 2024
zacks.com
Monday, 11 November 2024
globenewswire.com
Wednesday, 6 November 2024
globenewswire.com
Thursday, 31 October 2024
globenewswire.com
Tuesday, 29 October 2024
zacks.com
Thursday, 10 October 2024
globenewswire.com
Friday, 4 October 2024
zacks.com
Wednesday, 25 September 2024
zacks.com
Tuesday, 24 September 2024
globenewswire.com
Friday, 20 September 2024
globenewswire.com
Friday, 6 September 2024
globenewswire.com
Thursday, 29 August 2024
globenewswire.com
Tuesday, 13 August 2024
seekingalpha.com
zacks.com
Wednesday, 10 July 2024
zacks.com
zacks.com
Tuesday, 18 June 2024
prnewswire.com
globenewswire.com
Monday, 3 June 2024
globenewswire.com
Wednesday, 8 May 2024
seekingalpha.com
Zacks Investment Research
Wednesday, 1 May 2024
GlobeNewsWire
Thursday, 28 March 2024
Seeking Alpha
Monday, 25 March 2024
GlobeNewsWire
Thursday, 21 March 2024
Zacks Investment Research
  • What's the price of Zevra Therapeutics stock today?

    One share of Zevra Therapeutics stock can currently be purchased for approximately $9.18.

  • When is Zevra Therapeutics's next earnings date?

    Unfortunately, Zevra Therapeutics's (ZVRA) next earnings date is currently unknown.

  • Does Zevra Therapeutics pay dividends?

    No, Zevra Therapeutics does not pay dividends.

  • How much money does Zevra Therapeutics make?

    Zevra Therapeutics has a market capitalization of 449.42M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 162.58% to 27.46M US dollars.

  • What is Zevra Therapeutics's stock symbol?

    Zevra Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "ZVRA".

  • What is Zevra Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Zevra Therapeutics?

    Shares of Zevra Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Zevra Therapeutics have?

    As Jul 2024, Zevra Therapeutics employs 65 workers, which is 103% more then previous quarter.

  • When Zevra Therapeutics went public?

    Zevra Therapeutics, Inc. is publicly traded company for more then 10 years since IPO on 16 Apr 2015.

  • What is Zevra Therapeutics's official website?

    The official website for Zevra Therapeutics is zevra.com.

  • Where are Zevra Therapeutics's headquarters?

    Zevra Therapeutics is headquartered at 1180 Celebration Boulevard, Celebration, FL.

  • How can i contact Zevra Therapeutics?

    Zevra Therapeutics's mailing address is 1180 Celebration Boulevard, Celebration, FL and company can be reached via phone at +32 19 39 34 16.

Zevra Therapeutics company profile:

Zevra Therapeutics, Inc.

zevra.com
Exchange:

NASDAQ

Full time employees:

65

Industry:

Biotechnology

Sector:

Healthcare

Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077, which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase II clinical trial. In addition, the company has received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. The company's product pipeline include, arimoclomol It has collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

1180 Celebration Boulevard
Celebration, FL 34747

CIK: 0001434647
ISIN: US4884452065
: